Alerts will be sent to your verified email
Verify Email
TLL
|
Trident Lifeline
|
Fredun Pharma
|
Balaxi Pharma.
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Unclassified
|
|||
|
Advertisement Spend as a % of Total Sales
|
0.37 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
35.94 % | 8.53 % | 29.33 % |
|
5yr average Equity Multiplier
|
1.91 | 3.02 | 1.4 |
|
5yr Average Asset Turnover Ratio
|
0.9 | 1.01 | 1.5 |
|
5yr Avg Net Profit Margin
|
17.11 % | 2.89 % | 11.83 % |
|
Price to Book
|
5.56 | 2.5 | 1.34 |
|
P/E
|
27.21 | 17.4 | 10.54 |
|
5yr Avg Cash Conversion Cycle
|
94.4 Days | 137.13 Days | 133.11 Days |
|
Inventory Days
|
68.55 Days | 140.46 Days | 68.7 Days |
|
Days Receivable
|
104.41 Days | 52.11 Days | 81.67 Days |
|
Days Payable
|
126.58 Days | 131.93 Days | 60.92 Days |
|
5yr Average Interest Coverage Ratio
|
17.94 | 2.31 | 92.41 |
|
5yr Avg ROCE
|
29.15 % | 16.75 % | 40.34 % |
|
5yr Avg Operating Profit Margin
|
16.89 % | 8.32 % | 18.05 % |
|
5 yr average Debt to Equity
|
0.34 | 0.86 | 0.05 |
|
5yr CAGR Net Profit
|
9.93 % | 52.4 % | n/a |
|
5yr Average Return on Assets
|
15.87 % | 3.05 % | 20.09 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
63.04 % | 48.93 % | 65.99 % |
|
Share Pledged by Promoters
|
3.46 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-6.53 % | -2.34 % | -6.87 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Trident Lifeline
|
Fredun Pharma
|
Balaxi Pharma.
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|